

CURRICULUM VITAE

PERSONAL INFORMATION

Yosuke TOGASHI, M.D., Ph.D.



EDUCATION, POSTDOCTORAL TRAINING, ACADEMIC APPOINTMENT

2000-2006: Kyoto University School of Medicine, M.D., Kyoto, Japan

2011-2012: Assistant Professor, Department of Multidisciplinary Cancer Treatment, Graduate School of Medicine and Faculty of Medicine Kyoto University, Kyoto, Japan

2012-2015: Graduate School of Medicine, Kindai University, Ph.D., Osaka, Japan

2014-2015: Research Fellowship for Young Scientist, Japan Society for the Promotion of Science

2015-2016: Assistant Professor, Department of Genome Biology, Kindai University, Osaka, Japan.

2016-2019: Researcher, Division of Cancer Immunology, National Cancer Center, Chiba, Japan

2017-2018: Research Fellowship for Young Scientist, Japan Society for the Promotion of Science

2019-2021: Division Head, Chiba Cancer Center, Research Institute

2021-present: Professor, Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University

2024-present: Professor, OKAYAMA UNIVERSITY HOSPITAL, Department of Allergy and Respiratory Medicine

SPECIALITY and FIELD of INTEREST

Pulmonary medicine, translational research, cancer immunology, and immune metabolism

RECENT SELECTED PUBLICATION

1. Ninomiya T and **Togashi Y (last corresponding author)**. Myeloid Cells Induce Infiltration and Activation of B Cells and CD4⁺ T Follicular Helper Cells to Sensitize Brain Metastases to Combination Immunotherapy. *Cancer Res.* 85: 1082-1096, 2025.
2. Ikeda H and **Togashi Y (last corresponding author)**. Immune Evasion through Mitochondrial Transfer in the Tumour Microenvironment. *Nature* 638: 225-236, 2025.
3. Mukohara F, Iwata K, Ishino T and **Togashi Y (last corresponding author)**. Somatic Mutations in Tumor-Infiltrating Lymphocytes Impact on Antitumor Immunity. *Proc Natl Acad Sci U S A.* 121: e2320189121, 2024.
4. Naoi Y, Morinaga T, and **Togashi Y (last corresponding author)**, et al. CD106 in tumor-specific exhausted CD8⁺ T cells mediates immunosuppression by inhibiting TCR signaling. *Cancer Res.* 84: 2109-2122, 2024.
5. Zhou W, Nagasaki J, and **Togashi Y (last corresponding author)**, et al. Stem-like Progenitor and Terminally Differentiated T_{FH}-like CD4⁺ T cell Exhaustion in the Tumor Microenvironment. *Cell Rep.* 27: 113797, 2024.
6. Kawase K, Kawashima S, and **Togashi Y (last corresponding author)**, et al. High major histocompatibility complex class I expression overcomes cancer immunotherapy resistance due to interferon gamma signaling pathway. *Caner Immunol Res.* 11: 895-908, 2023.
7. Kawashima S and Togashi Y (**last corresponding author**), et al. TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment. *J Immunother Cancer.* 9: e003134, 2021.
8. Nagasaki J, Inozume T, and **Togashi Y (last corresponding author)**, et al. PD-1 blockade therapy promotes infiltration of tumor-attacking exhausted T cell clonotypes. *Cell Rep.* 38: 110331, 2022.
9. Kumagai S, **Togashi Y (co-1st)**, Kamada T, et al. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. *Nat Immunol* 21: 1346-1358, 2020.
10. Kumagai S, **Togashi Y (corresponding author)**, Sakai S, et al. Metabolic advantage conferred by a driver gene alteration maintains Treg cell abundance and function in the tumor microenvironment. *Immunity* 53: 187-203, 2020.
11. Sugiyama E, **Togashi Y (co-1st)**, Takeuchi Y, et al. Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non-small cell lung cancer. *Sci Immunol* 5: eaav3937, 2020..
12. Tanegashima T, **Togashi Y (corresponding author)**, Azuma K, et al. Immune suppression by PD-L2 against spontaneous and treatment-related antitumor immunity. *Clin Cancer Res* 25: 4808-4819, 2019.
13. Kamada T, **Togashi Y (co-1st)**, Tay C, et al. PD-1⁺ regulatory T cells are activated by PD-1 blockade and contribute to hyperprogression of cancer. *Proc Natl Acad Sci USA* 116: 9999-10008, 2019.
14. **Togashi Y**, Shitara K, Nishikawa H. Treg cells in cancer immunosuppression - Implications for anticancer therapy. *Nat Rev Clin Oncol* 16: 356-371, 2019.

Biography

Yosuke Togashi earned his M.D. from Kyoto University School of Medicine in 2006 and initially worked as a clinician in the Department of Respiratory Medicine. After serving as an Assistant Professor at Kyoto University, he obtained his Ph.D. in Genome Biology at Kindai University in 2015. His early career was distinguished by a research fellowship at the Japan Society for the Promotion of Science. He subsequently began basic and translational research in cancer immunology as a postdoctoral fellow at the National Cancer Center (Nishikawa Lab) in 2016. Since 2021, he has been a Professor at Okayama University, focusing on translational research of the tumor microenvironment. Additionally, he has been a Professor at OKAYAMA UNIVERSITY HOSPITAL, Department of Allergy and Respiratory Medicine, concurrently since 2024.